No5 barrister at the head of the debate on pricing of rare drugs

Wed, 17 Nov 2010

No5 barrister David Lock is quoted in this week’s edition of the British Medical Journal in connection with the controversy over the pricing of rare drugs, which has seen 20 leading doctors write in protest to the Prime Minister about the conduct of drug companies.
 
Drug companies are attempting to persuade the NHS to prescribe expensive drugs which have an EU “marketing authorisation” in preference to much cheaper, generic drugs which have a similar clinical effect but have no marketing authorisation.
 
David has given advice to the NHS, which the NHS then chose to publish, that it would be likely to be lawful for NHS bodies to refuse to allow doctors to prescribe branded drug where there is a generic drug which delivers similar clinical outcomes at a lower cost. 
 
 

Related articles

On the 24th May from 5pm to 6pm, Founder and Trustee of City Disabilities, Robert Hunter, will be presenting a webinar...

Date: Tue, 18 May 2021
Three No5 barristers Saleema Mahmood, Nabila Mallick and Sultana Tafadar have appeared as guests on Ramadan Radio in a live discussion on Breaking Stereotypes episode ‘Your career, your faith’....

Date: Fri, 23 Apr 2021
No5 is delighted to announce that Esther Gamble has been named “Barrister of the Year” by the Birmingham Law Society....

Date: Mon, 19 Apr 2021